Market Overview

UPDATE: Morgan Stanley Upgrades Medtronic Following Acquisition Of COV

Related MDT
Benzinga's Top Upgrades
Medtronic Launches superDimension Lung Navigation Software With Suggested Fiducial Marker Placement
My K.I.S.S. Dividend Portfolio: 3rd Quarter 2015 Update (Seeking Alpha)

In a report published Tuesday, Morgan Stanley analyst David R. Lewis upgraded the rating on Medtronic (NYSE: MDT) from Equal-Weight to Overweight, and named a $73.00 price target.

In the report, Morgan Stanley noted, “We are upgrading MDT to Overweight following its transformational acquisition of COV. The initial muted reaction (-1%) fails to appreciate greater financial upside through cost and tax synergies and peer leading capital deployment flexibility which should drive >10% returns.”

Medtronic closed on Monday at $60.03.

Latest Ratings for MDT

Oct 2015Evercore ISI GroupUpgradesHoldBuy
Sep 2015JefferiesMaintainsHold
Sep 2015Cowen & CompanyMaintainsOutperform

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Upgrades Analyst Ratings


Related Articles (MDT)

View Comments and Join the Discussion!

Get Benzinga's Newsletters